Pembrolizumab treatment of advanced neuroendocrine tumors: Results from the phase II KEYNOTE-158 study.
Year: 2019
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Jonathan R. Strosberg, Nobumasa Mizuno, Toshihiko Doi, Enrique Grande, Jean-Pierre Delord, Ronnie Shapira-Frommer, Emily K. Bergsland, Manisha H. Shah, Marwan Fakih, Shunji Takahashi, Sarina Anne Piha-Paul, Bert O'Neil, Sajeve Thomas, Martijn P. Lolkema, Jiang Dian Wang, Nageatte Ibrahim, Scott K. Pruitt, Julien Hadoux
Institutions: Moffitt Cancer Center, Aichi Cancer Center, National Cancer Center Hospital East, MD Anderson Cancer Center Madrid, Institut universitaire du cancer de Toulouse Oncopole, Institut Claudius Regaud, Sheba Medical Center, University of California, San Francisco, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, City Of Hope National Medical Center, The Cancer Institute Hospital, Japanese Foundation For Cancer Research, The University of Texas MD Anderson Cancer Center, Indiana University Health, Indiana University Hospital, Erasmus MC, Merck & Co., Inc., Rahway, NJ, USA (United States), Institut Gustave Roussy
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2912484087